Aligos Therapeutics Elects New Directors, Amends Bylaws
Ticker: ALGS · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-composition, governance, bylaws
TL;DR
Aligos adds 2 directors, updates bylaws. Board shakeup incoming?
AI Summary
Aligos Therapeutics, Inc. announced on June 27, 2024, a series of significant corporate actions. These include the election of two new directors, Dr. David P. Gryaznov and Ms. Jennifer L. D. Fox, to its Board of Directors, effective immediately. The company also disclosed compensatory arrangements for certain officers and amendments to its bylaws.
Why It Matters
The addition of new directors and amendments to corporate governance documents can signal strategic shifts or preparations for future growth or challenges within the company.
Risk Assessment
Risk Level: medium — Changes in board composition and bylaws can indicate internal shifts that may impact future strategy and performance.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- Dr. David P. Gryaznov (person) — Newly elected director
- Ms. Jennifer L. D. Fox (person) — Newly elected director
- June 27, 2024 (date) — Date of earliest event reported
FAQ
Who are the newly elected directors to Aligos Therapeutics' Board?
Dr. David P. Gryaznov and Ms. Jennifer L. D. Fox were elected to the Board of Directors.
When were the new directors elected?
The election of the new directors was effective as of June 27, 2024.
What other corporate actions were reported in this 8-K?
The filing also reported on compensatory arrangements of certain officers and amendments to the company's bylaws.
What is the state of incorporation for Aligos Therapeutics?
Aligos Therapeutics, Inc. is incorporated in Delaware.
What is the primary business of Aligos Therapeutics?
Aligos Therapeutics is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 1,376 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-06-28 16:00:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
Filing Documents
- d129014d8k.htm (8-K) — 46KB
- d129014dex31.htm (EX-3.1) — 8KB
- d129014dex101.htm (EX-10.1) — 4KB
- 0001193125-24-172218.txt ( ) — 193KB
- algs-20240627.xsd (EX-101.SCH) — 3KB
- algs-20240627_lab.xml (EX-101.LAB) — 19KB
- algs-20240627_pre.xml (EX-101.PRE) — 12KB
- d129014d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aligos Therapeutics, Inc. 10.1 Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: June 28, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer